Ethiodized Oil (Ethiodol)

Ethyl ester of iodinated fatty acid of poppyseed oil. It contains 37% organically bound iodine and has been used as a diagnostic aid (radiopaque medium) and as an antineoplastic agent when part of the iodine is 131-I. (From Merck Index, 11th ed)
Also Known As:
Ethiodol; Lipiodol; Aspen Brand of Ethiodized Oil; Ethiodized Oil (Injection); Ethiodized Oils; Ethiodized Poppy Seed Oil; Guerbet Brand of Ethiodized Oil; Lipiodol UltraFluid; Savage Brand of Ethiodized Oil; Therapex Brand of Ethiodized Oil; Oil, Ethiodized; Oils, Ethiodized; UltraFluid, Lipiodol
Networked: 1331 relevant articles (109 outcomes, 168 trials/studies)

Relationship Network

Drug Context: Research Results


1. Garin, Etienne: 10 articles (03/2012 - 10/2004)
2. Chung, Jin Wook: 9 articles (09/2015 - 11/2002)
3. Jeong, Jae Min: 9 articles (03/2015 - 10/2003)
4. Raoul, Jean-Luc: 8 articles (06/2011 - 11/2003)
5. Morris, D L: 8 articles (01/2008 - 03/2000)
6. Matsui, Osamu: 7 articles (04/2014 - 11/2006)
7. Chen, Yong: 7 articles (09/2013 - 10/2003)
8. Park, Jae Hyung: 7 articles (06/2013 - 11/2002)
9. Kim, Hyo-Cheol: 6 articles (09/2015 - 11/2009)
10. Sato, Morio: 6 articles (08/2015 - 06/2010)

Related Diseases

1. Hepatocellular Carcinoma (Hepatoma)
2. Neoplasms (Cancer)
3. Liver Neoplasms (Liver Cancer)
03/01/2015 - "The newly synthesized (188)Re-HDD/lipiodol showed improved radiolabeling yield and biodistribution results compared to (188)Re-HTDD/lipiodol, and may therefore be more suitable for liver cancer therapy."
07/01/2010 - "Reported CR ratio of definitely hypervascular HCC are around 30-60% by superselective TACE with Lipiodol for hypervascular HCC less than 5 cm. According to a nationwide survey by the Liver Cancer Study Group of Japan (LCSGJ), overall 5-year survival rate was 26% in patients with HCCs not indicated for surgery or RFA (PEI), mainly treated by segmental or subsegmental TACE using Lipiodol. "
03/01/2008 - "The Nuclear Medicine Section of IAEA's Division of Human Health initiated the first Doctoral CRP of IAEA in the year 2000, entitled, "Management of Liver Cancer Using Radionuclide Methods with Special Emphasis on Trans-Arterial Radio-conjugate Therapy and Internal Dosimetry." Since then, the CRP has accomplished several milestones, including development of a new therapeutic radiopharmaceutical ((188)Re lipiodol) and successfully carrying out Phase I and Phase II clinical trials on patients using the new therapeutic radiopharmaceutical."
01/01/2007 - "A lipiodol solution of (188)Re-4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol ((188)Re-HDD/lipiodol) is in clinical study for liver cancer therapy. "
03/01/2015 - "A lipiodol solution of (188)Re-4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol (HTDD) has been successfully developed for liver cancer therapy; however, its preparation requires a multi-step synthesis and it is characterized by a low labeling yield. "
4. Neoplasm Metastasis (Metastasis)
5. Carcinoma (Carcinomatosis)

Related Drugs and Biologics

1. Cisplatin (Platino)
2. Ethanol (Ethyl Alcohol)
3. Epirubicin (Ellence)
4. Ethiodized Oil (Ethiodol)
5. poly(maleic acid-styrene)neocarzinostatin (zinostatin stimalamer)
6. Doxorubicin (Adriamycin)
7. Iodine
8. Mitomycin (Mitomycin-C)
9. Enbucrilate
10. alpha-Fetoproteins (AFP)

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Intra-Arterial Injections
3. Catheters
4. Palliative Care (Palliative Medicine)
5. Absorbable Gelatin Sponge